Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2025-05-13 Major Shareholding Noti…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils (articles L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Articles L. 233-7 of the Commercial Code)'. This type of filing in France (indicated by the AMF reference and French text) reports when a shareholder's stake crosses specific ownership thresholds (like 5%). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant share ownership levels crossing thresholds. The code for this is MRQ.
2025-05-13 French
Franchissement de seuil
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuil (articles L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold' under French commercial law. It explicitly states that Great Point Partners LLC crossed the 5% threshold of INVENTIVA's capital on May 5, 2025, and details the resulting shareholding (5.32% of capital). This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure regarding ownership changes, not a general regulatory announcement (RNS) or a report itself.
2025-05-13 French
Inventiva obtient la deuxième tranche de 116 millions d'euros de son financement structuré d'un montant maximum de 348 millions d'euros
Capital/Financing Update Classification · 98% confidence The document is a press release dated May 5, 2025, announcing that Inventiva has secured the second tranche (€116 million) of its structured financing deal. The text details the terms of the issuance, including the creation of new shares (Actions Nouvelles) and warrants (BSA/PFW-BSA), the use of proceeds (funding Phase 3 clinical trials), and the impact on working capital. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes, which corresponds to the 'Capital/Financing Update' definition. It is not an Annual Report (10-K), an Earnings Release (ER), or an Interim Report (IR) as it focuses on the financing event itself, not the periodic financial results. It is a specific announcement about capital raising, making 'CAP' the most appropriate code.
2025-05-05 French
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that Inventiva has secured the second tranche of a structured financing deal (€116 million). It details the terms of the financing, the use of proceeds (to finance the Phase 3 clinical trial for lanifibranor), and the structure involving new shares, warrants (ABSAs and PFW-BSAs), and pre-funded warrants. This activity directly relates to the company raising capital and changing its capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a financing event.
2025-05-05 English
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires
AGM Information Classification · 98% confidence The document is a press release dated April 30, 2025, announcing the modalities for making preparatory documents available for the upcoming Annual General Meeting (Assemblée Générale Mixte) scheduled for May 22, 2025. Key phrases include "Assemblée Générale Mixte du 22 mai 2025," "modalités de mise à disposition des documents préparatoires," and references to the notice of meeting ("avis de réunion") and resolutions. This content directly relates to the logistics and materials surrounding a shareholder meeting, which aligns best with the 'AGM Information' category. Although it is a press release announcing AGM details, the core subject matter is the AGM itself, making AGM-R more specific than RPA or RNS, especially since it details where and when the AGM documents will be available.
2025-04-30 French
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
AGM Information Classification · 98% confidence The document is titled "Combined General Meeting of May 22, 2025 Availability of the preparatory documents" and explicitly announces that the preparatory documents for the Combined General Meeting (AGM) are now available. It details where shareholders can access these documents (website, registered office) and the procedures for requesting them. This content directly relates to the materials and announcements surrounding a shareholder meeting, fitting the definition of AGM Information (AGM-R). Although it mentions other filings (like the 20-F and URD), the primary purpose of this specific press release is to announce the availability of AGM materials.
2025-04-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.